A Study of Infliximab in Patients With Sarcoidosis

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients must have been diagnosed with sarcoidosis at least 1 year prior to entry into the study

• Patients must have laboratory test diagnosing sarcoidosis prior to screening

• Patients must have a diagnosis of sarcoidosis by chest x- ray

Exclusion Criteria:

• Patients must not have used any investigational drug within 1 month prior to entering the study

• Patients must not have received previous administration of a treatment with any other therapeutic agent targeted at reducing TNF such as pentoxifylline, thalidomide, etanercept, CDP 870, adalimumab, within 3 months prior to screening

• Patients must not have received vaccinations within 3 months